Biogen Idec gains on Tecfidera approval

Biogen Idec Inc. (NASDAQ:BIIB) was up $9.94 to $192.62 on Thursday on the heels of FDA's approval

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE